Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
10.72 USD | -2.63% | -8.60% | +18.02% |
May. 13 | Avalo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 17 | North American Morning Briefing : Stock Futures -2- | DJ |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 11.39M |
---|---|---|---|---|---|
Net income 2024 * | -33M | Net income 2025 * | -36M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-12.1
x | P/E ratio 2025 * |
-11.4
x | Employees | 19 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 0% |
1 day | +0.09% | ||
1 week | -8.86% | ||
Current month | -5.78% | ||
1 month | -23.33% | ||
3 months | +144.67% | ||
6 months | -24.05% | ||
Current year | +20.99% |
Managers | Title | Age | Since |
---|---|---|---|
Garry Neil
CEO | Chief Executive Officer | 70 | 20-01-31 |
Director of Finance/CFO | 40 | 17-12-31 | |
Dino Miano
COO | Chief Operating Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
June Almenoff
BRD | Director/Board Member | 67 | 21-11-09 |
Gilla Kaplan
BRD | Director/Board Member | 76 | 20-10-11 |
Garry Neil
CEO | Chief Executive Officer | 70 | 20-01-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-06 | 10.74 | -2.45% | 4 387 |
24-06-05 | 11.01 | +0.09% | 11,326 |
24-06-04 | 11 | -3.93% | 9,984 |
24-06-03 | 11.45 | -2.01% | 15,506 |
24-05-31 | 11.68 | -0.55% | 12,696 |
Delayed Quote Nasdaq, June 05, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+20.99% | 11.39M | |
+55.70% | 59.34B | |
+42.89% | 40.24B | |
-5.39% | 39.88B | |
-5.56% | 28.55B | |
+16.46% | 27.26B | |
-20.56% | 19.23B | |
+33.03% | 12.61B | |
+25.85% | 12.28B | |
+2.72% | 12.49B |
- Stock Market
- Equities
- AVTX Stock